Skip to main content

Gaining sage on the Epoetins' saga: assessing long term risks and advancing towards better Epoetin driven treatment modalities

Objetivo

EpoCan aims to develop and implement a comprehensive interdisciplinary strategy to assess the long-term risks of erythropoietin (EPO) and its derivatives (epoetins) on tumour growth progression and thromboembolic events in cancer patients, cardiovascular events, and the development of cancer in chronic kidney disease. Approximately 400,000 patients across Europe receive epoetins treatment each year. Recent meta-analysis data have raised concerns over increased mortality in some patient groups. Hence the urgent need to evaluate the risk-benefit ratio of epoetin treatment and its potential long-term effects.
EpoCan brings together a multidisciplinary consortium of 12 world leading academic, industrial and medical partners, with long-standing, complementary expertise in haemostasis, oncology and EPO biology. EpoCan aims to (1) Identify, detect and measure possible long-term hazards of epoetin treatment; (2) Develop novel prognostic tools and new complementary therapeutic reagents: (3) Evaluate the risk-benefit ratio to pave the way for new safety and efficacy criteria.
EpoCan will: (a) Utilize a wide array of cellular models to thoroughly analyze EPO/EPO receptor(EPO-R)interaction and signalling, to define the relationship between EPO-R expression in tumour samples and the clinical outcome in cancer patients; (b) Establish and test new, personalized, predictive tools (EPO-R peptide antagonists, novel specific anti-EPO-R monoclonal antibodies, thromboembolic tests); (c) Create new murine models as hosts for tumour implantation subjected to EPO and derivatives established above; (d) Screen and analyze clinical databases; (e) Define models to predict hazardous versus safe/beneficial roles of epoetins in the treatment of cancer and kidney failure associated anaemia. Data obtained will be integrated into coherent models using novel computational algorithms developed for EpoCan. Results are expected to have broad ramifications, with special relevance for clinical oncology.

Convocatoria de propuestas

FP7-HEALTH-2011-single-stage
Consulte otros proyectos de esta convocatoria

Coordinador

TEL AVIV UNIVERSITY
Dirección
Ramat Aviv
69978 Tel Aviv
Israel

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Drorit Neumann (Prof.)
Aportación de la UE
€ 350 400

Participantes (12)

THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
Aportación de la UE
€ 233 520
Dirección
University Road Lanyon Building
BT7 1NN Belfast

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Terence Lappin (Prof.)
University of Zurich
Suiza
Aportación de la UE
€ 301 680
Dirección
Ramistrasse 71
8006 Zurich

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Max Gassmann (Prof.)
UNIVERSITAET DUISBURG-ESSEN
Alemania
Aportación de la UE
€ 240 600
Dirección
Universitatsstrasse 2
45141 Essen

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Joachim Fandrey (Prof.)
UNIVERSIDAD AUTONOMA DE MADRID
España
Aportación de la UE
€ 291 200
Dirección
Calle Einstein 3 Ciudad Univ Cantoblanco Rectorado
28049 Madrid

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Mª Carmen Puerta (Ms.)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Países Bajos
Aportación de la UE
€ 298 160
Dirección
Heidelberglaan 100
3584 CX Utrecht

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Mark Roest (Dr.)
ACADEMISCH ZIEKENHUIS LEIDEN
Países Bajos
Aportación de la UE
€ 281 600
Dirección
Albinusdreef 2
2333 ZA Leiden

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Jaco Graaf (Mr.)
VETERINAERMEDIZINISCHE UNIVERSITAET WIEN
Austria
Aportación de la UE
€ 241 173,60
Dirección
Veterinaerplatz 1
1210 Vienna

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Thomas Rülicke (Prof.)
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
Aportación de la UE
€ 132 038,40
Dirección
Christoph Probst Platz 1
6020 Innsbruck

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Ludger Hengst (Prof.)
DEUTSCHES HERZZENTRUM MUNCHEN
Alemania
Aportación de la UE
€ 180 520
Dirección
Lazarettstrasse 36
80636 Munich

Ver en el mapa

Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contacto administrativo
Ilka Ott (Prof.)
ALDEVRON FREIBURG GMBH
Alemania
Aportación de la UE
€ 162 471,60
Dirección
Waltershofener Strasse 17
79111 Freiburg

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
John Thompson (Dr.)
WINZSOFT (ISRAEL) LTD
Israel
Aportación de la UE
€ 161 280
Dirección
Beit Hillel 3
67017 Tel Aviv-jaffo

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Marcus-Kalish Mira (Dr.)
OSM-DAN LTD
Israel
Aportación de la UE
€ 120 460
Dirección
19 Pro Neeman Yuval St
7608665 Rehovot

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Pnina Dan (Dr.)